{"id":3463,"date":"2026-01-18T18:04:36","date_gmt":"2026-01-18T17:04:36","guid":{"rendered":"https:\/\/fhucare.com\/?page_id=3463"},"modified":"2026-01-19T12:48:00","modified_gmt":"2026-01-19T11:48:00","slug":"immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3","status":"publish","type":"page","link":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/","title":{"rendered":"Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3)"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:70%\">\n<p>Management of adverse events, modulation of autoimmunity, modulating microbiome treatment to cure cancer.<\/p>\n\n\n\n<div class=\"wp-block-group has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-12dd3699 wp-block-group-is-layout-constrained\">\n<p class=\"is-style-text-annotation is-style-text-annotation--1\" style=\"margin-top:var(--wp--preset--spacing--30);margin-bottom:var(--wp--preset--spacing--30);padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\"><strong>WP3 Leader : <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Aur\u00e9lien-Marabelle\">Aur\u00e9lien Marabelle<\/a> (also vice-coordinator of the project)<\/strong><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:30%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"600\" height=\"600\" src=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg.png\" alt=\"\" class=\"wp-image-3492\" srcset=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg.png 600w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg-500x500.png 500w, https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg-150x150.png 150w\" sizes=\"auto, (max-width: 600px) 100vw, 600px\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div data-wp-context=\"{ &quot;autoclose&quot;: false, &quot;accordionItems&quot;: [] }\" data-wp-interactive=\"core\/accordion\" role=\"group\" class=\"wp-block-accordion is-layout-flow wp-block-accordion-is-layout-flow\">\n<div data-wp-class--is-open=\"state.isOpen\" data-wp-context=\"{ &quot;id&quot;: &quot;accordion-item-2&quot;, &quot;openByDefault&quot;: true }\" data-wp-init=\"callbacks.initAccordionItems\" data-wp-on-window--hashchange=\"callbacks.hashChange\" class=\"wp-block-accordion-item is-open is-layout-flow wp-block-accordion-item-is-layout-flow\">\n<h3 class=\"wp-block-accordion-heading\"><button aria-expanded=\"true\" aria-controls=\"accordion-item-2-panel\" data-wp-bind--aria-expanded=\"state.isOpen\" data-wp-on--click=\"actions.toggle\" data-wp-on--keydown=\"actions.handleKeyDown\" id=\"accordion-item-2\" class=\"wp-block-accordion-heading__toggle\" style=\"padding-top:var(--wp--preset--spacing--40)\"><span class=\"wp-block-accordion-heading__toggle-icon\" aria-hidden=\"true\">+<\/span><span class=\"wp-block-accordion-heading__toggle-title\"><a href=\"javascript:void(0)\">Task 1: Immunotox: a network for managing immune related adverse events (IrAEs) of ICI<\/a><\/span><\/button><\/h3>\n\n\n\n<div aria-labelledby=\"accordion-item-2\" data-wp-bind--inert=\"!state.isOpen\" id=\"accordion-item-2-panel\" role=\"region\" class=\"wp-block-accordion-panel is-layout-flow wp-block-accordion-panel-is-layout-flow\">\n<p>ICI have revolutionized the treatment of many cancers but the price to pay is the development of IrAEs in a substantial number of patients. Interestingly, patients developing IrAEs could have a better chance of tumor response. Thus, it is crucial to continue ICI in those patients and to correctly manage these side effects. <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Olivier-Lambotte\"><strong>Olivier Lambotte<\/strong><\/a>, <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Aur\u00e9lien-Marabelle\"><strong>Aur\u00e9lien Marabelle<\/strong><\/a> and <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Benjamin-Besse\"><strong>Benjamin Besse<\/strong><\/a> have set up a network called Immunotox of physicians both in IGR and Paris-Saclay hospitals for managing these IrAEs. FHU CARE allows to develop and consolidate this network with the involvement of basic scientists. Recommendations of management are provided for each organ disease involved by IrAEs.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div data-wp-class--is-open=\"state.isOpen\" data-wp-context=\"{ &quot;id&quot;: &quot;accordion-item-3&quot;, &quot;openByDefault&quot;: false }\" data-wp-init=\"callbacks.initAccordionItems\" data-wp-on-window--hashchange=\"callbacks.hashChange\" class=\"wp-block-accordion-item is-layout-flow wp-block-accordion-item-is-layout-flow\">\n<h3 class=\"wp-block-accordion-heading\"><button aria-expanded=\"false\" aria-controls=\"accordion-item-3-panel\" data-wp-bind--aria-expanded=\"state.isOpen\" data-wp-on--click=\"actions.toggle\" data-wp-on--keydown=\"actions.handleKeyDown\" id=\"accordion-item-3\" class=\"wp-block-accordion-heading__toggle\"><span class=\"wp-block-accordion-heading__toggle-icon\" aria-hidden=\"true\">+<\/span><span class=\"wp-block-accordion-heading__toggle-title\"><a href=\"javascript:void(0)\">Task 2: Incidence and evolution of AID associated with thymic malignancies<\/a><\/span><\/button><\/h3>\n\n\n\n<div inert aria-labelledby=\"accordion-item-3\" data-wp-bind--inert=\"!state.isOpen\" id=\"accordion-item-3-panel\" role=\"region\" class=\"wp-block-accordion-panel is-layout-flow wp-block-accordion-panel-is-layout-flow\">\n<p>The proof of this concept has emerged from the simultaneous occurrence of lung cancer and scleroderma in patients with anti-Pol 3 antibodies due to the occurrence of a crossed immunity between mutated and wild-type Pol 3 (Joseph, Science 2014). This concept has been confirmed with the spectacular efficacy of ICI. We extend this concept:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Development of very sensitive technics for detecting cancer cells in patients developing an AID. If <strong>autoimmunity may be a way of curing cancer,<\/strong> we look at the presence of very rare cancer cells in patients with AID.<\/li>\n\n\n\n<li>Modulation of the autoimmune response induced by ICI to better control cancer. it has been shown that overexpression of TNF at the cancer side could impair the effect of ICI. With DITEP (<a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Aur\u00e9lien-Marabelle\"><strong>Aur\u00e9lien Marabelle<\/strong><\/a>) we design new protocols of treatment combining ICI and TNFi or ICI and IL-1\u03b2 or IL-6 inhibitors.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<div data-wp-class--is-open=\"state.isOpen\" data-wp-context=\"{ &quot;id&quot;: &quot;accordion-item-4&quot;, &quot;openByDefault&quot;: false }\" data-wp-init=\"callbacks.initAccordionItems\" data-wp-on-window--hashchange=\"callbacks.hashChange\" class=\"wp-block-accordion-item is-layout-flow wp-block-accordion-item-is-layout-flow\">\n<h3 class=\"wp-block-accordion-heading\"><button aria-expanded=\"false\" aria-controls=\"accordion-item-4-panel\" data-wp-bind--aria-expanded=\"state.isOpen\" data-wp-on--click=\"actions.toggle\" data-wp-on--keydown=\"actions.handleKeyDown\" id=\"accordion-item-4\" class=\"wp-block-accordion-heading__toggle\"><span class=\"wp-block-accordion-heading__toggle-icon\" aria-hidden=\"true\">+<\/span><span class=\"wp-block-accordion-heading__toggle-title\"><a href=\"javascript:void(0)\">Task 3: Modulating microbiome for treating AID\/ID and cancer<\/a><\/span><\/button><\/h3>\n\n\n\n<div inert aria-labelledby=\"accordion-item-4\" data-wp-bind--inert=\"!state.isOpen\" id=\"accordion-item-4-panel\" role=\"region\" class=\"wp-block-accordion-panel is-layout-flow wp-block-accordion-panel-is-layout-flow\">\n<p>Microbiota analyses could identify responders to ICI. Manipulation of the gut microbiome (i.e., fecal transplantation or microbial complementation) may increase its efficacy and safety in those who have the unfavourable microbiota. More specifically, <strong>maintaining a balance between immunogenic and tolerogenic gut ecosystems<\/strong> may be obtained by restoring eubiosis, either by transferring healthy microbiota (as already performed in severe colitis after ICI or in IBD (Wang, Nat Med. 2018) or by oral feeding with immunogenic (A. muciniphila, E. hirae, B. fragilis (rev. in <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Laurence-Zitvogel\">Zitvogel L<\/a>, Science 2018) or tolerogenic (F. prausnitzii, (Alameddine, Front Immunol. 2019) bacteria as well as specific diet interventions (prebiotics or metabolites) modulating distinct T cell subsets. <strong>Preclinical models and ongoing clinical trials at IGR and INRA<\/strong> pave the way to these novel therapeutic interventions.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div data-wp-class--is-open=\"state.isOpen\" data-wp-context=\"{ &quot;id&quot;: &quot;accordion-item-5&quot;, &quot;openByDefault&quot;: false }\" data-wp-init=\"callbacks.initAccordionItems\" data-wp-on-window--hashchange=\"callbacks.hashChange\" class=\"wp-block-accordion-item is-layout-flow wp-block-accordion-item-is-layout-flow\">\n<h3 class=\"wp-block-accordion-heading\"><button aria-expanded=\"false\" aria-controls=\"accordion-item-5-panel\" data-wp-bind--aria-expanded=\"state.isOpen\" data-wp-on--click=\"actions.toggle\" data-wp-on--keydown=\"actions.handleKeyDown\" id=\"accordion-item-5\" class=\"wp-block-accordion-heading__toggle\"><span class=\"wp-block-accordion-heading__toggle-icon\" aria-hidden=\"true\">+<\/span><span class=\"wp-block-accordion-heading__toggle-title\"><a href=\"javascript:void(0)\">Task 4: IrAEs may give a new vision of pathophysiology of AID<\/a><\/span><\/button><\/h3>\n\n\n\n<div inert aria-labelledby=\"accordion-item-5\" data-wp-bind--inert=\"!state.isOpen\" id=\"accordion-item-5-panel\" role=\"region\" class=\"wp-block-accordion-panel is-layout-flow wp-block-accordion-panel-is-layout-flow\">\n<p><strong>IrAEs may be considered as an experimental model of AID.<\/strong> But frequently, the emerging AID does not fulfill all the characteristics of the classical AID. Thus, <strong>these IrAEs may give new clues on pathophysiology of AID\/ID.<\/strong> ICI-induced sicca and SS <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Xavier-Mariette\"><strong>Xavier Mariette<\/strong><\/a>, ICI-induced colitis and IBD <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Franck-Carbonnel\"><strong>Franck Carbonnel<\/strong><\/a>, ICI-induced nephritis <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Antoine-Durrbach\"><strong>Antoine Durrbach<\/strong><\/a> are studied, with the help of pathology departments of FHU CARE <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Jean-Yves-Scoazec\"><strong>Jean-Yves Scoazec<\/strong><\/a> and <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Sophie-Ferlicot\"><strong>Sophie Ferlicot<\/strong><\/a>.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div data-wp-class--is-open=\"state.isOpen\" data-wp-context=\"{ &quot;id&quot;: &quot;accordion-item-6&quot;, &quot;openByDefault&quot;: false }\" data-wp-init=\"callbacks.initAccordionItems\" data-wp-on-window--hashchange=\"callbacks.hashChange\" class=\"wp-block-accordion-item is-layout-flow wp-block-accordion-item-is-layout-flow\">\n<h3 class=\"wp-block-accordion-heading\"><button aria-expanded=\"false\" aria-controls=\"accordion-item-6-panel\" data-wp-bind--aria-expanded=\"state.isOpen\" data-wp-on--click=\"actions.toggle\" data-wp-on--keydown=\"actions.handleKeyDown\" id=\"accordion-item-6\" class=\"wp-block-accordion-heading__toggle\"><span class=\"wp-block-accordion-heading__toggle-icon\" aria-hidden=\"true\">+<\/span><span class=\"wp-block-accordion-heading__toggle-title\"><a href=\"javascript:void(0)\">Task 5: Involvement of check-point inhibitors (ICI) in chronic infectious diseases<\/a><\/span><\/button><\/h3>\n\n\n\n<div inert aria-labelledby=\"accordion-item-6\" data-wp-bind--inert=\"!state.isOpen\" id=\"accordion-item-6-panel\" role=\"region\" class=\"wp-block-accordion-panel is-layout-flow wp-block-accordion-panel-is-layout-flow\">\n<p>Numerous works have shown involvement of ICI in HIV, HBV, HCV infections, in tuberculosis and other infections. <strong>ICI have been used in chronic infections in animal models.<\/strong> Like in cancers, this strategy could be limited by irAEs. <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Olivier-Lambotte\"><strong>Olivier Lambotte<\/strong><\/a> and <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Roger-Le-Grand\"><strong>Roger Le Grand<\/strong><\/a> study the effect of ICI in macaques\u2019 models of SIV infection and in human PML, a deadly infection. The schemes of ICI administration are different compared with cancer, that may help to understand the occurrence of irAEs. In parallel, <strong>safety of ICI in HIV-infected patients with cancer<\/strong> is studied in collaboration with the ANRS (<a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Olivier-Lambotte\"><strong>Olivier Lambotte<\/strong><\/a> and <a href=\"https:\/\/fhucare.com\/fhu-care2\/experts-and-network\/#Laurence-Meyer\"><strong>Laurence Meyer<\/strong><\/a>).<\/p>\n\n\n\n<p><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Timetable, deliverables and other proposed indicators<\/h2>\n\n\n\n<div data-wp-context=\"{ &quot;autoclose&quot;: false, &quot;accordionItems&quot;: [] }\" data-wp-interactive=\"core\/accordion\" role=\"group\" class=\"wp-block-accordion is-layout-flow wp-block-accordion-is-layout-flow\">\n<div data-wp-class--is-open=\"state.isOpen\" data-wp-context=\"{ &quot;id&quot;: &quot;accordion-item-7&quot;, &quot;openByDefault&quot;: false }\" data-wp-init=\"callbacks.initAccordionItems\" data-wp-on-window--hashchange=\"callbacks.hashChange\" class=\"wp-block-accordion-item is-layout-flow wp-block-accordion-item-is-layout-flow\">\n<h3 class=\"wp-block-accordion-heading\"><button aria-expanded=\"false\" aria-controls=\"accordion-item-7-panel\" data-wp-bind--aria-expanded=\"state.isOpen\" data-wp-on--click=\"actions.toggle\" data-wp-on--keydown=\"actions.handleKeyDown\" id=\"accordion-item-7\" class=\"wp-block-accordion-heading__toggle\"><span class=\"wp-block-accordion-heading__toggle-title\"><a href=\"javascript:void(0)\">WP3, Task 1: Immunotox: a network for managing immune related adverse events (IrAEs) of ICI<\/a><\/span><span class=\"wp-block-accordion-heading__toggle-icon\" aria-hidden=\"true\">+<\/span><\/button><\/h3>\n\n\n\n<div inert aria-labelledby=\"accordion-item-7\" data-wp-bind--inert=\"!state.isOpen\" id=\"accordion-item-7-panel\" role=\"region\" class=\"wp-block-accordion-panel is-layout-flow wp-block-accordion-panel-is-layout-flow\">\n<ul class=\"wp-block-list\">\n<li>D3.1.1: Connection of Immunotox with basic scientists D3.1.2: Recommendations of management for each organ disease involved by IrAEs.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<div data-wp-class--is-open=\"state.isOpen\" data-wp-context=\"{ &quot;id&quot;: &quot;accordion-item-8&quot;, &quot;openByDefault&quot;: false }\" data-wp-init=\"callbacks.initAccordionItems\" data-wp-on-window--hashchange=\"callbacks.hashChange\" class=\"wp-block-accordion-item is-layout-flow wp-block-accordion-item-is-layout-flow\">\n<h3 class=\"wp-block-accordion-heading\"><button aria-expanded=\"false\" aria-controls=\"accordion-item-8-panel\" data-wp-bind--aria-expanded=\"state.isOpen\" data-wp-on--click=\"actions.toggle\" data-wp-on--keydown=\"actions.handleKeyDown\" id=\"accordion-item-8\" class=\"wp-block-accordion-heading__toggle\"><span class=\"wp-block-accordion-heading__toggle-title\"><a href=\"javascript:void(0)\">WP3, Task 2: Inducing or modulating autoimmunity for curing cancer<\/a><\/span><span class=\"wp-block-accordion-heading__toggle-icon\" aria-hidden=\"true\">+<\/span><\/button><\/h3>\n\n\n\n<div inert aria-labelledby=\"accordion-item-8\" data-wp-bind--inert=\"!state.isOpen\" id=\"accordion-item-8-panel\" role=\"region\" class=\"wp-block-accordion-panel is-layout-flow wp-block-accordion-panel-is-layout-flow\">\n<ul class=\"wp-block-list\">\n<li>D3.2.1: Design of a clinical trial in one human cancer with a combination of ICI and a biologic targeting inflammation (TNF, IL1 or IL6)<\/li>\n\n\n\n<li>D3.2.2: Mechanism of anti-cancer action of a combination of ICI with a biologic targeting inflammation (TNF, IL1 or IL6)<\/li>\n\n\n\n<li>D3.2.3: A new sensitive technique for detecting cancer cells in AID<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<div data-wp-class--is-open=\"state.isOpen\" data-wp-context=\"{ &quot;id&quot;: &quot;accordion-item-9&quot;, &quot;openByDefault&quot;: false }\" data-wp-init=\"callbacks.initAccordionItems\" data-wp-on-window--hashchange=\"callbacks.hashChange\" class=\"wp-block-accordion-item is-layout-flow wp-block-accordion-item-is-layout-flow\">\n<h3 class=\"wp-block-accordion-heading\"><button aria-expanded=\"false\" aria-controls=\"accordion-item-9-panel\" data-wp-bind--aria-expanded=\"state.isOpen\" data-wp-on--click=\"actions.toggle\" data-wp-on--keydown=\"actions.handleKeyDown\" id=\"accordion-item-9\" class=\"wp-block-accordion-heading__toggle\"><span class=\"wp-block-accordion-heading__toggle-title\"><a href=\"javascript:void(0)\">WP3, Task 3: Modulating microbiome for treating AID\/ID and cancer<\/a><\/span><span class=\"wp-block-accordion-heading__toggle-icon\" aria-hidden=\"true\">+<\/span><\/button><\/h3>\n\n\n\n<div inert aria-labelledby=\"accordion-item-9\" data-wp-bind--inert=\"!state.isOpen\" id=\"accordion-item-9-panel\" role=\"region\" class=\"wp-block-accordion-panel is-layout-flow wp-block-accordion-panel-is-layout-flow\">\n<ul class=\"wp-block-list\">\n<li>D3.3.1: Proof of concept of modulation of microbiota for improving efficacy of ICI in animal models<\/li>\n\n\n\n<li>D3.3.2: Design of a clinical trial in one human cancer to test the concept<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Management of adverse events, modulation of autoimmunity, modulating microbiome treatment to cure cancer. WP3 Leader : Aur\u00e9lien Marabelle (also vice-coordinator of the project) Timetable, deliverables and other proposed indicators<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3439,"menu_order":15,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3463","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3) - FHU CARE\u00b2<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3) - FHU CARE\u00b2\" \/>\n<meta property=\"og:description\" content=\"Management of adverse events, modulation of autoimmunity, modulating microbiome treatment to cure cancer. WP3 Leader : Aur\u00e9lien Marabelle (also vice-coordinator of the project) Timetable, deliverables and other proposed indicators\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU CARE\u00b2\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T11:48:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg.png\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\\\/\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\\\/\",\"name\":\"Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3) - FHU CARE\u00b2\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/naturalKiller-bg.png\",\"datePublished\":\"2026-01-18T17:04:36+00:00\",\"dateModified\":\"2026-01-19T11:48:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/naturalKiller-bg.png\",\"contentUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/naturalKiller-bg.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Axes\",\"item\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"WPs 2020-2024\",\"item\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/research-axes\\\/wps-2020-2024\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\",\"name\":\"FHU CARE\u00b2\",\"description\":\"Innovations in Autoimmunity, Cancer &amp; Immunotherapies\",\"publisher\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\"},\"alternateName\":\"CARE2\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\",\"name\":\"FHU CARE\u00b2\",\"alternateName\":\"CARE2\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/CARE2-COULEUR.svg\",\"contentUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/CARE2-COULEUR.svg\",\"caption\":\"FHU CARE\u00b2\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/fhucare\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@fhucare\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3) - FHU CARE\u00b2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/","og_locale":"fr_FR","og_type":"article","og_title":"Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3) - FHU CARE\u00b2","og_description":"Management of adverse events, modulation of autoimmunity, modulating microbiome treatment to cure cancer. WP3 Leader : Aur\u00e9lien Marabelle (also vice-coordinator of the project) Timetable, deliverables and other proposed indicators","og_url":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/","og_site_name":"FHU CARE\u00b2","article_modified_time":"2026-01-19T11:48:00+00:00","og_image":[{"width":600,"height":600,"url":"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/","url":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/","name":"Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3) - FHU CARE\u00b2","isPartOf":{"@id":"https:\/\/fhucare.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/#primaryimage"},"image":{"@id":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/#primaryimage"},"thumbnailUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg.png","datePublished":"2026-01-18T17:04:36+00:00","dateModified":"2026-01-19T11:48:00+00:00","breadcrumb":{"@id":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/#primaryimage","url":"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg.png","contentUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2026\/01\/naturalKiller-bg.png"},{"@type":"BreadcrumbList","@id":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer-wp3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhucare.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Research Axes","item":"https:\/\/fhucare.com\/fr\/research-axes\/"},{"@type":"ListItem","position":3,"name":"WPs 2020-2024","item":"https:\/\/fhucare.com\/fr\/research-axes\/wps-2020-2024\/"},{"@type":"ListItem","position":4,"name":"Immune-Related Adverse Events (irAEs) in the immunotherapy of cancer (WP3)"}]},{"@type":"WebSite","@id":"https:\/\/fhucare.com\/fr\/#website","url":"https:\/\/fhucare.com\/fr\/","name":"FHU CARE\u00b2","description":"Innovations in Autoimmunity, Cancer &amp; Immunotherapies","publisher":{"@id":"https:\/\/fhucare.com\/fr\/#organization"},"alternateName":"CARE2","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhucare.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/fhucare.com\/fr\/#organization","name":"FHU CARE\u00b2","alternateName":"CARE2","url":"https:\/\/fhucare.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fhucare.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/CARE2-COULEUR.svg","contentUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/CARE2-COULEUR.svg","caption":"FHU CARE\u00b2"},"image":{"@id":"https:\/\/fhucare.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/in\/fhucare\/","https:\/\/www.youtube.com\/@fhucare\/"]}]}},"_links":{"self":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages\/3463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/comments?post=3463"}],"version-history":[{"count":3,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages\/3463\/revisions"}],"predecessor-version":[{"id":3535,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages\/3463\/revisions\/3535"}],"up":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/pages\/3439"}],"wp:attachment":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/media?parent=3463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}